pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rybrevant Faspro
drug
save

(amivantamab + hyaluronidase (human recombinant))

Marketedupdated 3mo ago
by $JNJ JOHNSON & JOHNSON
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval4 co-mentions · 2 sources
  • drugamivantamab4 co-mentions · 2 sources
  • drugRYBREVANT FASPRO4 co-mentions · 2 sources
  • drugRYBREVANT2 co-mentions · 2 sources
  • companyJanssen Biotech Inc2 co-mentions · 2 sources

indications

investigational
NSCLC

all catalysts(2)

approval · 2
Dec 17, 2025
approval
8mo ago
RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approval
(amivantamab + hyaluronidase (human recombinant))
→
Feb 13, 2026
approval
6mo ago
RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approval
(amivantamab + hyaluronidase (human recombinant))
→

News(0)

no news has mentioned this drug yet

brand
Rybrevant Faspro
generic
(amivantamab + hyaluronidase-rhu (human recombinant))
indication
Recurrent Head And Neck Squamous Cell Carcinoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 16m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?